HC Wainwright Reiterates “Buy” Rating for TransCode Therapeutics (NASDAQ:RNAZ)

TransCode Therapeutics (NASDAQ:RNAZ)‘s stock had its “buy” rating reaffirmed by research analysts at HC Wainwright in a research note issued on Thursday,Benzinga reports. They currently have a $20.00 price target on the stock. HC Wainwright’s target price points to a potential upside of 68.18% from the company’s current price.

TransCode Therapeutics Trading Up 33.0 %

Shares of NASDAQ:RNAZ traded up $2.95 during trading on Thursday, hitting $11.89. The company’s stock had a trading volume of 11,597,825 shares, compared to its average volume of 3,996,321. TransCode Therapeutics has a fifty-two week low of $2.66 and a fifty-two week high of $66.33. The stock’s 50-day moving average price is $32.08 and its two-hundred day moving average price is $295.96.

Institutional Investors Weigh In On TransCode Therapeutics

A hedge fund recently raised its stake in TransCode Therapeutics stock. Sheets Smith Wealth Management lifted its position in TransCode Therapeutics, Inc. (NASDAQ:RNAZ) by 149.0% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 50,138 shares of the company’s stock after buying an additional 30,000 shares during the period. Sheets Smith Wealth Management owned approximately 0.29% of TransCode Therapeutics worth $29,000 at the end of the most recent reporting period.

About TransCode Therapeutics

TransCode Therapeutics, Inc, a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others.